Prerpints.org logo
Preprint
Article

This version is not peer-reviewed.

SARS-CoV-2 phoenix: Empirical formulas and thermodynamic properties (enthalpy, entropy and Gibbs energy) of nucleocapsid, virus particle and biosynthesis of BA.2.86 Pirola variant

Submitted:

27 September 2023

Posted:

28 September 2023

You are already at the latest version

Preprints on COVID-19 and SARS-CoV-2
Abstract
Similarly to a phoenix, SARS-CoV-2 has appeared periodically in waves. The new variants that appeared through mutations have during the 4 years of the pandemic suppressed earlier variants, causing new waves of the pandemic. The Omicron BA.2.86 Pirola variant is the latest in the sequence of SARS-CoV-2 variants, which appeared in 2023. The BA.2.86 variant has started to spread rapidly and we are witnesses of a new epidemic wave. In this short period, an increased infectivity was noticed, which results in rapid spreading and decreased pathogenicity, which results in a lower number of severe cases. However, in the public there is a fear of further development of the epidemic. This analysis was made with the goal to assess the risks in the period of late 2023. Mutations that were developed by the BA.2.86 variant have led to a change in empirical formula and thermodynamic properties. It seems that there is no ground for fear of an extensive spreading of severe forms, but there are reasons for caution and monitoring of the spreading of the epidemic and potential appearance of new mutations.
Keywords: 
Biothermodynamics
;  
Virus-host interaction
;  
COVID-19
;  
Pandemic
;  
Variant under monitoring
;  
Pathogenicity
;  
Pathogen
;  
August 2023
Subject: 
Biology and Life Sciences  -   Virology

Introduction

Phoenix is an immortal bird that cyclically regenerates. Like a phoenix, SARS-CoV-2 has cyclically regenerated several dozen times through mutations from Hu-1 to the newest Omicron BA.2.86 Pirola variant. With every new mutation and new variant, SARS-CoV-2 has obtained a new life appearing slightly different from its predecessor. Some of the variants have caused pandemic waves of high amplitude [Campi et al., 2022; Dutta, 2022; Nasir et al., 2023; Thakur et al., 2022; Amin et al., 2022]. Differently from the mythological phoenix, the SARS-CoV-2 phoenix has disappeared and reborn in front of our eyes during the three years of the pandemic. Thus, SARS-CoV-2 has appeared in late-2019 in Wuhan and was labeled as the Hu-1 wild type [Holmes et al., 2021; Hu et al., 2021; WHO, 2021; Andersen et al., 2020; Chan et al., 2020]. Mutations have occurred mostly in the part of the genome that encodes the spike glycoprotein [Magazine et al., 2022; Souza et al., 2022; Kumar et al., 2023; Harvey et al., 2021; Rahbar et al., 2021; Gobeil et al., 2021]. However, mutations have occurred in other viral proteins as well [Senthilazhagan et al., 2023; Ichikawa et al., 2022]. Evolution of viruses and formation of new variants has been described in the literature [ECDC, 2023a; CDC, 2023b; WHO, 2023b; Aleem et al., 2023; NCBI, 2023a; Carabelli et al., 2023; Chen et al., 2022; Rahman et al., 2022; Dubey et al., 2021; Singh et al., 2022; Ramesh et al., 2021; Popovic, 2023a, 2022b; Popovic et al., 2023a, 2023b].
BA.2.86 Pirola is the latest variant of SARS-CoV-2, which is characterized by many mutations [CDC, 2023a]. The number of mutations in BA.2.86 variant compared to the XBB.1.5 variant is similar to the difference between the first Omicron variant and its predecessor Delta variant [CDC, 2023a]. This might give the BA.2.86 variant the ability to infect people who have previously had COVID-19 or who have received COVID-19 vaccines [CDC, 2023a], which has raised concerns in the public [EuroNews, 2023; CNBC, 2023]. Globally, as of 30 August 2023, there have been 770,085,713 confirmed cases of COVID-19, including 6,956,173 deaths [WHO, 2023a]. Even though there has been a decrease in number of daily infections worldwide since late 2022, with the appearance of the new Omicron BA.2.86 variant, the number of COVID-19 cases has increased since the mid-2023. Due to this situation, it would be good to perform a physicochemical analysis of the BA.2.86 variant to compare its ability to infect host cells with that of the previous variants of SARS-CoV-2.
SARS-CoV-2 belongs to the Coronaviridae family [Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020; Yang et al., 2020; Rajagopalan, 2021; Abdelrahman et al., 2020; Zhu et al., 2020]. It is an enveloped virus, with a single stranded positive sense RNA genome [Bartas et al., 2022; Alexandersen et al., 2020; Cao et al., 2021; Brant et al., 2021; Lee et al., 2022; Chai et al., 2021]. SARS-CoV-2 virus particles contain four kinds of structural proteins: nucleocapsid (N), membrane (M), envelope (E) and spike (S) [Troyano-Hernáez et al., 2021; Satarker and Nampoothiri, 2020; Jackson et al., 2022; Schoeman and Fielding, 2019; Dolan et al., 2022; Yao et al., 2020]. The nucleocapsid protein binds to the viral RNA and forms the nucleocapsid [Wu et al., 2023, 2021; Cubuk et al., 2021; Perdikari et al., 2020; Jack et al., 2021; Wang et al., 2022]. The nucleocapsid is enclosed in a lipid bilayer envelope that contains membrane and envelope proteins [Kumar and Saxena, 2021; Ke et al., 2020; Hardenbrook and Zhang, 2022; Motsa and Stahelin, 2021; Mesquita et al., 2021; Mandala et al., 2020]. The spike proteins point out from the surface of the virus particle [Taha et al., 2023; Huang et al., 2020; Kordyukova et al., 2023; Chen et al., 2021; Zeng et al., 2021; Almehdi et al., 2021]. They represent the virus antigens that bind to host cell receptors [Gale, 2022; Popovic, 2023b, 2023c, 2023d; Popovic and Popovic, 2022].
SARS-CoV-2 belongs to RNA viruses [V’kovski et al., 2021; Khan et al., 2021; Zhang et al., 2021]. RNA viruses exhibit a great tendency to mutate [Duffy, 2018; Villa et al., 2021; Drake and Holland, 1999; Sanjuán and Domingo-Calap, 2016; Domingo et al., 2021; Elena et al., 2000; Dolan et al., 2018; Schulte et al., 2015; Popovic, 2022c]. Mutations lead to change in information content of the viral genome, chemical changes in elemental composition, as well as thermodynamic properties (enthalpy, entropy and Gibbs energy of formation and biosynthesis) [Popovic, 2022d, 2022e, 2022f]. Mutation as a biological phenomenon, except through sequencing, can be detected through the atom counting method, which allows detection of changes in elemental composition that appear as a consequence of mutations [Popovic, 2022g]. Furthermore, changes in elemental composition lead to changes in thermodynamic properties [Battley, 2013, 1999a, 1998; Battley and Stone, 2000; Patel and Erickson, 1981; Ozilgen and Sorgüven, 2017; Hurst and Harrison, 1992; Popovic, 2019; Popovic et al., 2021].
Since 2019, in the literature, elemental composition and thermodynamic properties have been reported for several virus species: Ebola [Popovic, 2022h], Monkeypox [Popovic, 2022a], SARS-CoV-2 [Şimşek et al., 2021; Degueldre, 2021; Gale, 2022; Popovic and Popovic, 2022; Popovic, 2022e, 2022d; Popovic et al., 2023a, 2023b; Popovic and Minceva, 2020b], MERS-CoV [Popovic and Minceva, 2020b], SARS-CoV [Popovic and Minceva, 2020b], HIV [Gale, 2020], arboviruses [Gale, 2020, 2019, 2018] and bacteriophages [Maskow et al., 2010; Guosheng et al., 2003; Popovic, 2023e]. Biothermodynamic mechanisms that influence infectivity and pathogenicity of different variants and the consequences on epidemiology and mechanisms of spreading of SARS-CoV-2 are available in the literature [Lucia et al., 2021, 2020a, 2020b; Kaniadakis et al., 2020; Head et al., 2022; Özilgen and Yilmaz, 2021; Pateras et al., 2022; Yilmaz et al., 2020; Trancossi et al., 2021].
The aim of this paper is to explore changes in empirical formula, molar mass, biosynthesis reactions, and thermodynamic properties (enthalpy, entropy, Gibbs energy) of formation and biosynthesis of the BA.2.86 Pirola variant. Based on the obtained results, the goal is to perform an assessment of the risk of spreading of an epidemic/pandemic of the BA.2.86 variant in late 2023. Moreover, the pathogenicity of the BA.2.86 variant will be compared to those of the earlier variants of SARS-CoV-2.

Methods

Data sources

The genetic sequence of the Omicron BA.2.86 Pirola variant of SARS-CoV-2 was taken from GISAID, the global data science initiative [Khare et al., 2021; Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017]. It can be found under the accession number EPI_ISL_18138566 and is labeled hCoV-19/USA/OH-ODH-SC3032044/2023. It was isolated on July 29, 2023 in Cuyahoga County, Ohio. Thus, the findings of this study are based on metadata associated with one sequence available on GISAID up to September 24, 2023, and accessible at https://doi.org/10.55876/gis8.230924yd (please see the Supplementary Material for more details).
The sequence of the nucleocapsid phosphoprotein of SARS-CoV-2 was obtained from the NCBI database [Sayers et al., 2022; NCBI, 2023b], under the accession number QIK50455.1 [NCBI, 2023c]. The sequence of the membrane protein of SARS-CoV-2 was obtained from the NCBI database [Sayers et al., 2022; NCBI, 2023a], under the accession number QHR63293.1 [NCBI, 2023d]. The sequence of the spike glycoprotein of SARS-CoV-2 was obtained from the NCBI database [Sayers et al., 2022; NCBI, 2023a], under the accession number QHR63290.2 [NCBI, 2023e]. The number of protein copies in the virus particle was taken from [Neuman and Buchmeier, 2016; Neuman et al., 2011; Neuman et al., 2006]. In a SARS-CoV-2 particle, there are 2368 copies of the nucleocapsid phosphoprotein, 1184 copies of the membrane protein and 222 copies of the spike glycoprotein [Neuman and Buchmeier, 2016; Neuman et al., 2011; Neuman et al., 2006].

Empirical formulas

The empirical formulas and molar masses of the virus particle and nucleocapsid of the Omicron BA.2.86 Pirola variant of SARS-CoV-2 were determined through the atom counting method [Popovic, 2022g]. They were determined based on the genetic sequence, protein sequences and virus morphology.
The atom counting method is a computational approach for determination of empirical formulas, chemical formulas and molar masses of macromolecules and macromolecular assemblies [Popovic, 2022g; Popovic et al., 2023c]. The atom counting method can analyze a wide range of macromolecules, including be double-stranded DNA, single-stranded DNA, single-stranded RNA, double-stranded RNA, proteins, polypeptides, oligopeptides etc. [Popovic, 2022g; Popovic et al., 2023c]. Furthermore, the atom counting method can be used to analyze macromolecular assemblies, such as virus particles, virus nucleocapsids, protein complexes, complexes of nucleic acids and proteins etc. [Popovic, 2022g; Popovic et al., 2023c].
The atom counting method is implemented with a computer program [Popovic, 2022g]. The input of the program are genetic sequences, protein sequences and morphological data [Popovic, 2022g]. The morphological data include protein copy numbers in macromolecular assemblies, size of the macromolecular assembly, whether the macromolecular assembly possesses lipids and carbohydrates etc. [Popovic, 2022g]. The output of the atom counting method are chemical formulas of macromolecules, empirical formulas of macromolecules, chemical formulas of macromolecular assemblies, empirical formulas of macromolecular assemblies, molar masses of empirical formulas of macromolecules, molar masses of empirical formulas of macromolecular assemblies, molar masses of macromolecules and molar masses of macromolecular assemblies [Popovic, 2022g].
The program that implements the atom counting method goes along the sequences of macromolecules (e.g. nucleic acids or proteins), which consist of residues [Popovic, 2022g]. Every residue has a well-defined chemical formula [Popovic, 2022g]. Thus, the program adds the atoms of different elements that come from every residue [Popovic, 2022g]. This gives the chemical formula of the macromolecule [Popovic, 2022g]. In case of macromolecular assemblies, the numbers of atoms of different elements are multiplied by the numbers of copies of the macromolecule in the macromolecular assembly [Popovic, 2022g]. If a macromolecular assembly contains lipids, the atoms coming from lipids are taken into account based on morphological data [Popovic, 2022g]. Then atoms coming from all the macromolecules are added to find the numbers of atoms of different elements in the macromolecular assembly [Popovic, 2022g]. These are used to find the empirical formula through the equation
n J = N J N C
where nJ is the number of atoms of element J in the empirical formula, NJ is the total number of atoms of element J in the molecule or macromolecular assembly, and NC is the total number of carbon atoms in the molecule or macromolecular assembly [Popovic, 2022g].

Thermodynamic properties of live matter

Thermodynamic properties of virus particle and nucleocapsid of the Omicron BA.2.86 variant were determined with the Patel-Erickson model [Patel and Erickson, 1981; Battley, 1998] and Battley model [Battley, 1999a; Battley and Stone, 2000]. They were determined based on empirical formulas. The Patel-Erickson model was used to find enthalpy [Patel and Erickson, 1981; Battley, 1998] and the Battley model was used to find entropy [Battley, 1999a; Battley and Stone, 2000], which were then combined to find Gibbs energy.
To find enthalpy of live matter (i.e. virus particle or nucleocapsid) with the Patel-Erickson model, the empirical formula is used to find the number of electrons transferred to oxygen during complete oxidation, E, with the equation [Patel and Erickson, 1981; Battley, 1998]
E = 4 n C + n H − 2 n O − 0   n N + 5 n P + 6 n S
E is then used to find standard enthalpy of combustion of live matter, ΔCH⁰, with the equation
∆ C H 0 b i o = − 111.14   k J C − m o l · E
The Patel-Erickson model is based on Thornton’s theory of combustion, sometimes called Thornton’s rule [Thornton, 1917]. Thornton’s rule states that the process that releases energy during combustion is acceptance of electrons by oxygen which is highly electronegative [Thornton, 1917]. ΔCH⁰ is then used to calculate standard enthalpy of formation of live matter, ΔfH⁰, with the equation [Battley, 1998, 1999b, 1992]
∆ f H 0 b i o = n C   ∆ f H 0 C O 2 + n H 2   ∆ f H 0 H 2 O + n P 4   ∆ f H 0 P 4 O 10 + n S   ∆ f H 0 S O 3 − ∆ C H 0
Entropy of live matter is calculated with the Battley model, based on its elemental composition. Standard molar entropy of live matter, S⁰m, is given by the equation
S m 0 b i o = 0.187   ∑ J S m 0 ( J ) a J n J
where S⁰m(J) is standard molar entropy of element J, aJ number of atoms of element J in its standard state elemental form, and nJ the number of atoms of element J in the empirical formula of live matter [Battley, 1999a; Battley and Stone, 2000]. The summation is over all elements J of which the live matter consists [Battley, 1999a; Battley and Stone, 2000]. The changed environment of the atoms of elements in live matter is taken into account by the constant 0.187. The Battley model can also be used to find standard entropy of formation of live matter, ΔfS⁰, if the constant 0.187 is changed to -0.813 [Battley, 1999a; Battley and Stone, 2000]
∆ f S 0 b i o = − 0.813   ∑ J S m 0 ( J ) a J n J
Finally, ΔfS⁰ and ΔfH⁰ are combined to find standard Gibbs energy of formation, ΔfG⁰, of live matter
∆ f G 0 b i o = ∆ f H 0 b i o − T ∆ f S 0 b i o
where T is temperature [Atkins and de Paula, 2011, 2014].

Biosynthesis reactions

Biosynthesis reactions of the virus particle and nucleocapsid of the Omicron BA.2.86 variant were formulated based on their empirical formulas. Biosynthesis reactions are macrochemical equations of conversion of nutrients into new live matter in metabolism [Assael et al., 2022; von Stockar, 2013a, 2013b; Battley, 2013, 1999b]. The general biosynthesis reaction for viruses has the form
(Amino acid) + O2 + HPO42− + HCO3− → (Bio) + SO42− + H2O + H2CO3
where (Amino acid) represents a mixture of amino acids, which has the empirical formula CH1.798O0.4831N0.2247S0.022472 [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c]. Newly synthetized live matter, (Bio), is represented with its empirical formula [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c]. The source of energy, carbon, nitrogen and sulfur for biosynthesis are the amino acids [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c]. The electron acceptor is O2 [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c; Annamalai, 2021]. The source of phosphorus is HPO42- [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c]. Excess H+ ions generated during biosynthesis are absorbed by the HCO3- ion, which is a part of the bicarbonate buffer [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c]. Excess sulfur atoms are released in the form of the SO42- ion, which is an additional metabolic product [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c]. The oxidized carbon atoms are released in the form of H2CO3, which is also a part of the bicarbonate buffer [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c].

Thermodynamic properties of biosynthesis

Thermodynamic properties of biosynthesis of the virus particle and nucleocapsid of the Omicron BA.2.86 variant of SARS-CoV-2 were calculated with the Hess’s law. They were found based on the biosynthesis reactions and thermodynamic properties of live matter. Thermodynamic properties of biosynthesis include standard enthalpy of biosynthesis, ΔbsH⁰, standard entropy of biosynthesis, ΔbsS⁰, and standard Gibbs energy of biosynthesis, ΔbsG⁰ [von Stockar, 2013a, 2013b]. They can be found by application of the Hess’s law to the biosynthesis reactions
∆ b s H 0 = ∑ p r o d u c t s ν   ∆ f H 0 − ∑ r e a c t a n t s ν   ∆ f H 0
∆ b s S 0 = ∑ p r o d u c t s ν   S m o − ∑ r e a c t a n t s ν     S m o
∆ b s G 0 = ∑ p r o d u c t s ν   ∆ f G 0 − ∑ r e a c t a n t s ν   ∆ f G 0
where ν represents a stoichiometric coefficient [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c; Atkins and de Paula, 2011, 2014; von Stockar, 2013b; Battley, 1998]. Of particular importance among these properties is ΔbsG⁰, since it represents the physical driving force for the process of multiplication of microorganisms [von Stockar, 2013a, 2013b; von Stockar and Liu, 1999], including viruses [Popovic et al., 2023a, 2023b; Popovic, 2023a, 2023b, 2022c].

Results

Empirical formulas and molar masses were determined for the first time for the virus particle and nucleocapsid of the Omicron BA.2.86 Pirola variant of SARS-CoV-2. They are shown in Table 1. The empirical formulas were determined through the atom counting method [Popovic, 2022g], based on the genetic sequence, protein sequences and morphology of the virus. The empirical formula of the virus particle of the Omicron BA.2.86 variant is CH1.639023O0.284130N0.230031P0.006440S0.003765 and has a molar mass of 21.75 g/C-mol. The molar mass of the entire virus particle of the Omicron BA.2.86 variant is 219.7 MDa. The empirical formula of the nucleocapsid of the Omicron BA.2.86 variant is CH1.570946O0.343118N0.312432P0.006007S0.003349 and has a molar mass of 23.75 g/C-mol. The molar mass of the entire nucleocapsid of the Omicron BA.2.86 variant is 117.6 MDa.
Table 2 shows thermodynamic properties of the virus particle and nucleocapsid of the Omicron BA.2.86 variant. They were determined through the Patel-Ericson model [Patel and Erickson, 1981; Battley, 1998] and Battley model [Battley, 1999a; Battley and Stone, 2000], based on the empirical formulas (Table 1). They include standard enthalpy of formation, ΔfH⁰, standard molar entropy, Sm⁰, and standard Gibbs energy of formation, ΔfG⁰. For the virus particle of the Omicron BA.2.86 variant, standard enthalpy of formation is -64.43 kJ/C-mol, standard molar entropy is 30.70 J/C-mol K and standard Gibbs energy of formation is -24.64 kJ/C-mol. For the nucleocapsid of the Omicron BA.2.86 variant, standard enthalpy of formation is -75.41 kJ/C-mol, standard molar entropy is 32.47 J/C-mol K and standard Gibbs energy of formation is -33.32 kJ/C-mol.
Table 3 shows the biosynthesis stoichiometry of the virus particle and nucleocapsid of the Omicron BA.2.86 variant. They were formulated based on the empirical formulas (Table 1). The general biosynthesis reaction has the form (Amino acid) + CH2O + O2 + HPO42- + HCO3- → (Bio) + SO22- + H2O + H2CO3, where (Amino acid) represents a mixture of amino acids with the formula CH1.798O0.4831N0.2247S0.022472 and (Bio) represents the empirical formula of live matter.
Table 4 gives thermodynamic properties of biosynthesis of the virus particle and nucleocapsid of the Omicron BA.2.86 variant of SARS-CoV-2. They were calculated with the Hess’s law [Atkins and de Paula, 2011, 2014; von Stockar, 2013a, 2013b], based on the biosynthesis stoichiometry (Table 3) and thermodynamic properties of live matter (Table 2). They include standard enthalpy of biosynthesis, ΔbsH⁰, standard entropy of biosynthesis, ΔbsS⁰, and standard Gibbs energy of biosynthesis, ΔbsG⁰. For the virus particle of the Omicron BA.2.86 variant, standard enthalpy of biosynthesis is -4.80 kJ/C-mol, standard entropy of biosynthesis is 6.94 J/C-mol K and standard Gibbs energy of biosynthesis is -6.94 kJ/C-mol. For the nucleocapsid of the Omicron BA.2.86 variant, standard enthalpy of biosynthesis is -232.88 kJ/C-mol, standard entropy of biosynthesis is -37.48 J/C-mol K and standard Gibbs energy of biosynthesis is -221.75 kJ/C-mol.

Discussion

Empirical formula and thermodynamic properties of live matter

The empirical formula of the virus particle of the Omicron BA.2.86 variant of SARS-CoV-2 is reported for the first time: CH1.639023O0.284130N0.230031P0.006440S0.003765 (Table 1). Empirical formulas have been reported in the literature for other SARS-CoV-2 variants. The empirical formula of the virus particle of the Hu-1 wild type of SARS-CoV-2 is CH1.6390O0.2851N0.2301P0.0065S0.0038 [Popovic and Minceva, 2020b]. The empirical formula of the virus particle of the Delta variant of SARS-CoV-2 is CH1.6383O0.2844N0.2294P0.0064S0.0042 [Popovic, 2022e]. The virus particle of the Omicron BA.1 variant of SARS-CoV-2 is characterized by the empirical formula CH1.6404O0.2842N0.2299P0.0064S0.0038 [Popovic, 2022e]. The empirical formula of the virus particle of the BA.2 variant of SARS-CoV-2 is CH1.6403O0.2838N0.2298P0.0064S0.0038 [Popovic, 2022f]. Moreover, empirical formulas of other virus species have been reported in the literature. The empirical formula of a Poxviridae virus particle is CH1.5876O0.3008N0.2538S0.00223P0.00554 [Popovic, 2022a]. A Vaccinia virus particle is characterized by the empirical formula CH1.5877O0.3232N0.2531P0.00371S0.00540 [Popovic, 2022a]. Therefore, every virus species and variant is characterized by a different empirical formula. Based on the empirical formula, it is possible to identify the virus. This provides a rapid method for virus identification through single particle inductively coupled plasma mass spectroscopy, as described by Degueldre [Degueldre, 2021].
Empirical formulas have been reported in the literature for various species of cellular organisms. The empirical formula of Escherichia coli (bacteria) is CH1.918O0.528N0.257P1.76×10⁻²S5.54×10⁻³K5.87×10⁻³Mg2.07×10⁻³Ca8.36×10⁻⁴Mn9.89×10⁻⁶Fe7.82×10⁻⁵Cu1.62×10⁻⁶Zn2.41×10⁻⁵ [Popovic et al., 2021]. The empirical formula of Penicillium chrysogenum (mold fungi) is CH2.026O0.511N0.185P9.15×10⁻³S4.17×10⁻³K3.45×10⁻³Mg1.47×10⁻³Ca3.69×10⁻⁴Mn1.08×10⁻⁵Fe9.51×10⁻⁵Cu1.24×10⁻⁶Zn2.15×10⁻⁵ [Popovic et al., 2021]. Saccharomyces cerevisiae (yeast fungi) is characterized by an empirical formula CH1.613O0.557N0.158P0.012S0.003K0.022Mg0.003Ca0.001 [Battley, 1999a]. The empirical formula of the human organism is CH1.7296O0.2591N0.1112P0.0134S0.003Na0.0027K0.0031Ca0.0173Cl0.0018 [Popovic and Minceva, 2020c]. The empirical formula of the virus particle of the Omicron BA.2.86 variant of SARS-CoV-2 is CH1.639023O0.284130N0.230031P0.006440S0.003765 (Table 1). Therefore, every class of organisms is characterized by a unique empirical formula different than those of other organisms.
Except for its empirical formula, the Omicron BA.2.86 variant of SARS-CoV-2 has its characteristic thermodynamic properties of live matter (enthalpy, entropy, Gibbs energy), which were determined in this research (Table 2). Gibbs energy of formation of the Omicron BA.2.86 virus particle is -24.64 kJ/C-mol, while that of the BA.2.86 nucleocapsid is -33.32 kJ/C-mol (Table 2). Therefore, the virus particle has a greater (less negative) Gibbs energy than the nucleocapsid. This means that the virus particle has a greater usable energy content. The reason for this are the lipids in the viral envelope. The SARS-CoV-2 virus particle contains a lipid envelope [Riedel et al., 2019]. The lipids in the envelope have a high energy content [Balmer, 2010]. Therefore, the usable energy content of the virus particle is greater than that of the nucleocapsid.
Gibbs energies of formation have been reported in the literature for other virus species and variants. The virus particle of the Hu-1 wild type of SARS-CoV-2 is characterized by a Gibbs energy of formation -24.8 kJ/C-mol [Popovic and Minceva, 2020b]. Gibbs energy of formation of the virus particle of the Omicron BA.2.86 variant of SARS-CoV-2 is -24.64 kJ/C-mol (Table 2). Thus, Gibbs energy of formation of the BA.2.86 variant is different than that of the Hu-1 wild type. Moreover, Gibbs energy of a Poxviridae virus particle is -25.3 kJ/C-mol [Popovic, 2022a], while that of a Vaccinia virus particle is -30.0 kJ/C-mol [Popovic, 2022a]. Thus, the virus particle of the Omicron BA.2.86 variant of SARS-CoV-2 has a different Gibbs energy of formation than those of the Vaccinia and Poxviridae virus particles. Therefore, every virus species and variant has a characteristic Gibbs energy of formation.
Gibbs energies of formation of cellular microorganisms can also be found in the literature. Gibbs energy of formation of some cellular microorganisms are: -66.98 kJ/C-mol for Escherichia coli bacteria, -87.07 kJ/C-mol for Saccharomyces cerevisiae yeast fungi and -18.99 kJ/C-mol for Penicillium chrysogenum mold fungi [Popovic, 2019]. Thus, Gibbs energies of these cellular microorganisms are different than that of the Omicron BA.2.86 variant of SARS-CoV-2 (-24.64 kJ/C-mol). Furthermore, Gibbs energy of formation of the human organism is -37.54 kJ/C-mol [Popovic and Minceva, 2020c], which is different than that of the Omicron BA.2.86 variant of SARS-CoV-2. This means that every class of organisms should have a characteristic Gibbs energy of formation, summarizing the usable energy content in its life matter.

Biosynthesis reaction and thermodynamic properties of biosynthesis

Based on the empirical formulas of the virus particle and nucleocapsid of the Omicron BA.2.86 Pirola variant of SARS-CoV-2, biosynthesis reactions were formulated. The biosynthesis reaction of the virus particle of the Omicron BA.2.86 variant is
1.023637 CH1.798O0.4831N0.2247S0.022472 + 0.010469 CH2O + 0.006440 HPO42− + 0.025596 HCO3− → CH1.639023O0.284130N0.230031P0.006440S0.003765 + 0.019238 SO22− + 0.067397 H2O + 0.059701 H2CO3
where CH1.798O0.4831N0.2247S0.022472 is the empirical formula of amino acids and CH1.639023O0.284130N0.230031P0.006440S0.003765 is the empirical formula of the BA.2.86 virus particle (Table 1). The biosynthesis reaction of the nucleocapsid of the Omicron BA.2.86 variant is
1.390323 CH1.798O0.4831N0.2247S0.022472 + 0.492478 O2 + 0.006007 HPO42− + 0.043774 HCO3− → CH1.570946O0.343118N0.312432P0.006007S0.003349 + 0.027894 SO22− + 0.055049 H2O + 0.434097 H2CO3
where CH1.570946O0.343118N0.312432P0.006007S0.003349 is the empirical formula of the BA.2.86 nucleocapsid (Table 1). The biosynthesis reaction of the BA.2.86 virus particle contains both amino acids and carbohydrates as an energy source, while that of the BA.2.86 nucleocapsid contains only amino acids. This means that biosynthesis of the BA.2.86 virus particle takes more energy than biosynthesis of the nucleocapsid alone. The reason for this is the higher energy content in the virus particle, due to the lipids in the viral envelope, as discussed above. The lipids in the viral envelope have a high energy content [Balmer, 2010]. This means that the virus particle that contains the lipid envelope takes more energy for biosynthesis than the nucleocapsid which doesn’t contain lipids. This energy comes from the carbohydrates in the biosynthesis reaction. The biosynthesis reaction of the BA.2.86 virus particle requires more hydrogen phosphate ion than that of the nucleocapsid. The HPO42- ion is the phosphorus source for biosynthesis. The higher amount of HPO42- in the biosynthesis reaction is due to phospholipids in the envelope of the virus particle.
Based on the biosynthesis reactions, thermodynamic properties of biosynthesis of the BA.2.86 variant were determined for the first time. Enthalpy of biosynthesis of the BA.2.86 variant nucleocapsid is -232.88 kJ/C-mol (Table 4). This means that the enthalpy of biosynthesis contributes favorably to the biosynthesis process. Entropy of biosynthesis of the BA.2.86 nucleocapsid -37.48 kJ/C-mol (Table 4). The negative entropy change is unfavorable for the biosynthesis reaction. Gibbs energy of biosynthesis of the BA.2.86 variant is -221.75 kJ/C-mol. The negative Gibbs energy, which is due to the negative enthalpy of biosynthesis, means that the biosynthesis process is thermodynamically favorable.

Virus-host and virus-virus interactions

Gibbs energy of biosynthesis represents the driving force for the biosynthesis process [Assael et al., 2022; von Stockar, 2013a, 2013b; von Stockar and Liu, 1999; Westerhoff et al., 1982; Hellingwerf et al., 1982; Demirel, 2014]. A more negative Gibbs energy of biosynthesis, ΔbsG, implies a greater biosynthesis rate, rbs, according to the biosynthesis phenomenological equation
r b s = − L b s T ∆ b s G
where Lbs is the biosynthesis phenomenological coefficient and T is temperature [Popovic, 2022c; Popovic, 2022e; Popovic et al., 2023a]. Gibbs energy of the biosynthesis of the nucleocapsid of the BA.2.86 Pirola variant of SARS-CoV-2 is -221.75 kJ/C-mol (Table 4). On the other hand, Gibbs energy of biosynthesis for the lung tissue is -49.76 kJ/C-mol [Popovic, 2022h]. Therefore, the BA.2.86 variant has a much more negative Gibbs energy of biosynthesis. This means that, according to the biosynthesis phenomenological equation, the biosynthesis rate of the BA.2.86 variant will be much greater than that of its host tissue. Due to this, the infected host cells will produce virus particles at a much greater rate than their own building blocks. This allows the hijacking of the host cell metabolism by the virus. The virus and its host cell compete for the cellular metabolic machinery and resources. The competition occurs in the host cell cytoplasm, at the ribosomes. The virus has a much greater driving force of biosynthesis, in the form of negative Gibbs energy. This means that the virus will have a much greater biosynthesis rate, which will allow it to hijack the host cell metabolism.
Gibbs energy of biosynthesis is proportional to the biosynthesis rate of a virus, according to the biosynthesis phenomenological equation. In case that several virus species or virus variants are simultaneously in circulation in the population, the virus with the most negative Gibbs energy of biosynthesis will have a competitive advantage [Popovic and Minceva, 2021; Popovic, 2023c]. The virus characterized by a more negative Gibbs energy of biosynthesis will have a greater biosynthesis rate [Popovic and Minceva, 2021; Popovic, 2023c]. This will allow it to dominate over other viruses circulating in the population [Popovic and Minceva, 2021; Popovic, 2023c]. Gibbs energy of biosynthesis of the nucleocapsid of the BA.2.86 Pirola variant of SARS-CoV-2 is -221.75 kJ/C-mol (Table 4). Gibbs energies of biosynthesis of nucleocapsids of other variants under monitoring are -221.21 for the Omicron CH.1.1 variant [Popovic, 2023a] and -221.19 kJ/C-mol for the Omicron XBB.1.16 variant [Popovic et al., 2023a]. Therefore, Gibbs energies of biosynthesis of the BA.2.86, CH.1.1 and XBB.1.16 variants are very similar. This means that in case these SARS-CoV-2 variants appear in a population, they will have very similar biosynthesis rates. This means that no variant will have an advantage in the competition. As a result, all three variants should circulate in the population during a pandemic wave and no variant should be able to suppress the other variants.
The concern expressed in the social media, concerning the greater pathogenicity of the new BA.2.86 variant seems not to be reasonable, since its Gibbs energy of biosynthesis is only slightly different than that of the other variants. The epidemiological measures that were undertaken in the fight against the other variants that caused the pandemic should result in an adequate response against the spreading of the BA.2.86 variant. However, the data related to kinetics of binding of the new variant to the host cell receptors are still not available. Therefore, in this work, it is not possible to predict with certainty the potential changes in infectivity of the new BA.2.86 variant compared to the other variants of SARS-CoV-2.

Conclusions

This research reports for the first time the empirical formula, molar mass, biosynthesis reactions and thermodynamic properties (enthalpy, entropy and Gibbs energy) of formation and biosynthesis of the Omicron BA.2.86 Pirola variant of SARS-CoV-2. The empirical formula of the BA.2.86 virus particle is CH1.639023O0.284130N0.230031P0.006440S0.003765, which has a molar mass of 21.75 g/C-mol. The empirical formula of the BA.2.86 variant is different than the empirical formulas of other SARS-CoV-2 variants, virus species and cellular organisms.
The nucleocapsid of the BA.2.86 variant is characterized by a Gibbs energy of biosynthesis of -221.75 kJ/C-mol. This is very similar to Gibbs energies of biosynthesis of the other variants under monitoring: CH.1.1 and XBB.1.16. Gibbs energy of biosynthesis represents the driving force for biosynthesis of virus particles and is proportional to their biosynthesis rate. Since the BA.2.86, CH.1.1 and XBB.1.16 variants have similar Gibbs energies of biosynthesis, they will have similar biosynthesis rates. This means that they will have very similar pathogenicity.

Supplementary Materials

The following supporting information can be downloaded at the website of this paper posted on Preprints.org.

Acknowledgments

We gratefully acknowledge all data contributors, i.e., the Authors and their Originating laboratories responsible for obtaining the specimens, and their Submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is based. This work was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (Grant No. 451-03-47/2023-01/200026).

Author statement

Marko E. Popović: Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing; Supervision Gavrilo Šekularac: Validation, Resources, Writing - Review & Editing, Funding acquisition.Marta Popović: Validation, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing.

Conflicts of Interest statement

The authors declare no conflict of interest.

References

  1. Abdelrahman, Z., Li, M., & Wang, X. (2020). Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Frontiers in immunology, 11, 552909. [CrossRef]
  2. Aleem, A., Akbar Samad, A. B., & Vaqar, S. (2023). Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). In StatPearls. StatPearls Publishing.
  3. Alexandersen, S., Chamings, A. & Bhatta, T.R. (2020). SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun 11, 6059. [CrossRef]
  4. Almehdi, A. M., Khoder, G., Alchakee, A. S., Alsayyid, A. T., Sarg, N. H., & Soliman, S. S. M. (2021). SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection, 49(5), 855–876. [CrossRef]
  5. Amin, R., Sohrabi, MR., Zali, AR. et al. (2022). Five consecutive epidemiological waves of COVID-19: a population-based cross-sectional study on characteristics, policies, and health outcome. BMC Infect Dis 22, 906. [CrossRef]
  6. Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020). The proximal origin of SARS-CoV-2. Nature medicine, 26(4), 450–452. [CrossRef]
  7. Annamalai, K. (2021). Oxygen Deficient (OD) Combustion and Metabolism: Allometric Laws of Organs and Kleiber’s Law from OD Metabolism? Systems, 9(3), 54. MDPI AG. [CrossRef]
  8. Assael, M.J., Maitland, G.C., Maskow, T., von Stockar, U., Wakeham, W.A. & Will, S. (2022). Commonly Asked Questions in Thermodynamics, 2nd ed. Boca Raton, FL: CRC Press. ISBN: 9780367338916. [CrossRef]
  9. Atkins, P. W., & de Paula, J. (2011). Physical Chemistry for the Life Sciences (2nd edition), W. H. Freeman and Company. ISBN-13: 978-1429231145.
  10. Atkins, P.W. & de Paula, J. (2014). Physical Chemistry: Thermodynamics, Structure, and Change, 10th Edition. New York: W. H. Freeman and Company. ISBN-13: 978-1429290197.
  11. Balmer, R.T. (2010). Modern Engineering Thermodynamics, Cambridge, MA: Academic Press. [CrossRef]
  12. Bartas, M., Volná, A., Beaudoin, C. A., Poulsen, E. T., Červeň, J., Brázda, V., Špunda, V., Blundell, T. L., & Pečinka, P. (2022). Unheeded SARS-CoV-2 proteins? A deep look into negative-sense RNA. Briefings in bioinformatics, 23(3), bbac045. [CrossRef]
  13. Battley E. H. (2013). A theoretical study of the thermodynamics of microbial growth using Saccharomyces cerevisiae and a different free energy equation. The Quarterly review of biology, 88(2), 69–96. [CrossRef]
  14. Battley, E. H., & Stone, J. R. (2000). A comparison of values for the entropy and the entropy of formation of selected organic substances of biological importance in the solid state, as determined experimentally or calculated empirically. Thermochimica acta, 349(1-2), 153-161. [CrossRef]
  15. Battley, E.H. (1999a). An empirical method for estimating the entropy of formation and the absolute entropy of dried microbial biomass for use in studies on the thermodynamics of microbial growth. Thermochimica Acta, 326(1-2), 7-15. [CrossRef]
  16. Battley, E.H. (1999b). The thermodynamics of microbial growth. In: Handbook of Thermal Analysis and Calorimetry, vol. 4: From Macromolecules to Man; E.B. Kemp, ed., Amsterdam: Elsevier, 219-235. [CrossRef]
  17. Battley, E.H. (1998). The development of direct and indirect methods for the study of the thermodynamics of microbial growth. Thermochimica Acta, 309 (1-2), 17-37. [CrossRef]
  18. Battley, E.H. (1992). On the enthalpy of formation of Escherichia coli K-12 cells, Biotechnology and Bioengineering, 39, 5-12. [CrossRef]
  19. Brant, A.C., Tian, W., Majerciak, V. et al. (2021). SARS-CoV-2: from its discovery to genome structure, transcription, and replication. Cell Biosci 11, 136. [CrossRef]
  20. Campi, G., Perali, A., Marcelli, A. et al. (2022). Sars-Cov2 world pandemic recurrent waves controlled by variants evolution and vaccination campaign. Sci Rep 12, 18108. [CrossRef]
  21. Cao, C., Cai, Z., Xiao, X. et al. (2021). The architecture of the SARS-CoV-2 RNA genome inside virion. Nat Commun 12, 3917. [CrossRef]
  22. Carabelli, A.M., Peacock, T.P., Thorne, L.G. et al. (2023). SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 21, 162–177. [CrossRef]
  23. CDC (2023a). Risk Assessment Summary for SARS CoV-2 Sublineage BA.2.86 [Online] Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/respiratory-viruses/whats-new/covid-19-variant.html#:~:text=Huma n%20cases%3A%20As%20of%20August,CDC's%20Traveler%2Dbased%20Genomic%20Surveillance (accessed on 31 August 2023).
  24. CDC (2023b). SARS-CoV-2 Variant Classifications and Definitions [Online] Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html (accessed on 5 September 2023).
  25. Chai, J., Cai, Y., Pang, C. et al. (2021). Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1. Nat Commun 12, 3433. [CrossRef]
  26. Chan, J. F., Yuan, S., Kok, K. H., To, K. K., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C., Poon, R. W., Tsoi, H. W., Lo, S. K., Chan, K. H., Poon, V. K., Chan, W. M., Ip, J. D., Cai, J. P., Cheng, V. C., Chen, H., Hui, C. K., … Yuen, K. Y. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England), 395(10223), 514–523. [CrossRef]
  27. Chen, Y., Liu, Q., Zhou, L., Zhou, Y., Yan, H., & Lan, K. (2022). Emerging SARS-CoV-2 variants: Why, how, and what's next?. Cell insight, 1(3), 100029. [CrossRef]
  28. Chen, Z., Du, R., Galvan Achi, J. M., Rong, L., & Cui, Q. (2021). SARS-CoV-2 cell entry and targeted antiviral development. Acta pharmaceutica Sinica. B, 11(12), 3879–3888. [CrossRef]
  29. CNBC (2023) New Covid-19 variant ‘Pirola’ or BA.2.86: Is it more dangerous, should India be worried? Here's all you need to know. Available online: https://www.cnbctv18.com/healthcare/new-covid-19-variant-pirola-or-ba286-is-it-more-dangerous-should-india-be-worried-heres-all-you-need-to-know-17673131.htm (accessed on 31 August 2023).
  30. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5, 536–544. [CrossRef]
  31. Cubuk, J., Alston, J.J., Incicco, J.J. et al. (2021). The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat Commun 12, 1936. [CrossRef]
  32. Degueldre, C. (2021). Single virus inductively coupled plasma mass spectroscopy analysis: A comprehensive study. Talanta, 228, 122211. 1222. [CrossRef]
  33. Demirel, Y. (2014). Nonequilibrium Thermodynamics: Transport and Rate Processes in Physical, Chemical and Biological Systems, 3rd ed. Amsterdam: Elsevier. ISBN: 9780444595812.
  34. Dolan, K. A., Dutta, M., Kern, D. M., Kotecha, A., Voth, G. A., & Brohawn, S. G. (2022). Structure of SARS-CoV-2 M protein in lipid nanodiscs. eLife, 11, e81702. [CrossRef]
  35. Dolan, P. T., Whitfield, Z. J., & Andino, R. (2018). Mechanisms and Concepts in RNA Virus Population Dynamics and Evolution. Annual review of virology, 5(1), 69–9. 1. [CrossRef]
  36. Domingo, E., García-Crespo, C., Lobo-Vega, R., & Perales, C. (2021). Mutation Rates, Mutation Frequencies, and Proofreading-Repair Activities in RNA Virus Genetics. Viruses, 13(9), 1882. [CrossRef]
  37. Drake, J. W., & Holland, J. J. (1999). Mutation rates among RNA viruses. Proceedings of the National Academy of Sciences of the United States of America, 96(24), 13910–13913. [CrossRef]
  38. Dubey, A., Choudhary, S., Kumar, P., & Tomar, S. (2021). Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. Current microbiology, 79(1), 20. [CrossRef]
  39. Duffy S. (2018). Why are RNA virus mutation rates so damn high?. PLoS biology, 16(8), e3000003. [CrossRef]
  40. Dutta, A. (2022) COVID-19 waves: variant dynamics and control. Sci Rep 12, 9332. [CrossRef]
  41. ECDC (2023). SARS-CoV-2 variants of concern as of 24 August 2023 [Online] European Centre for Disease Prevention and Control. Available online: https://www.ecdc.europa.eu/en/covid-19/variants-concern (accessed on 5 September 2023).
  42. Elbe, S. and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID’s innovative contribution to global health. Global Challenges, 1:33-46. [CrossRef]
  43. Elena, S. F., Miralles, R., Cuevas, J. M., Turner, P. E., & Moya, A. (2000). The two faces of mutation: extinction and adaptation in RNA viruses. IUBMB life, 49(1), 5–9. [CrossRef]
  44. EuroNews (2023). First Eris, now BA.2.86. Should we be worried about the latest, 'radically different' COVID variant? Available online: https://www.euronews.com/next/2023/08/22/first-eris-now-ba286-should-we-be-worried-about-the-latest-radically-different-covid-varia (accessed on 31 August 2023).
  45. Gale P. (2022). Using thermodynamic equilibrium models to predict the effect of antiviral agents on infectivity: Theoretical application to SARS-CoV-2 and other viruses. Microbial risk analysis, 21, 100198. [CrossRef]
  46. Gale P. (2020). How virus size and attachment parameters affect the temperature sensitivity of virus binding to host cells: Predictions of a thermodynamic model for arboviruses and HIV. Microbial risk analysis, 15, 100104. [CrossRef]
  47. Gale P. (2019). Towards a thermodynamic mechanistic model for the effect of temperature on arthropod vector competence for transmission of arboviruses. Microbial risk analysis, 12, 27–43. [CrossRef]
  48. Gale P. (2018). Using thermodynamic parameters to calibrate a mechanistic dose-response for infection of a host by a virus. Microbial risk analysis, 8, 1–13. [CrossRef]
  49. Gobeil, S. M., Janowska, K., McDowell, S., Mansouri, K., Parks, R., Stalls, V., Kopp, M. F., Manne, K., Li, D., Wiehe, K., Saunders, K. O., Edwards, R. J., Korber, B., Haynes, B. F., Henderson, R., & Acharya, P. (2021). Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science (New York, N.Y.), 373(6555), eabi6226. [CrossRef]
  50. Guosheng, L., Yi, L., Xiangdong, C., Peng, L., Ping, S., & Songsheng, Q. (2003). Study on interaction between T4 phage and Escherichia coli B by microcalorimetric method. Journal of virological methods, 112(1-2), 137–143. [CrossRef]
  51. Hardenbrook, N. J., & Zhang, P. (2022). A structural view of the SARS-CoV-2 virus and its assembly. Current opinion in virology, 52, 123–134. [CrossRef]
  52. Harvey, W.T., Carabelli, A.M., Jackson, B. et al. (2021). SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19, 409–424. [CrossRef]
  53. Head, R. J., Lumbers, E. R., Jarrott, B., Tretter, F., Smith, G., Pringle, K. G., Islam, S., & Martin, J. H. (2022). Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. Pharmacology research & perspectives, 10(1), e00922. [CrossRef]
  54. Hellingwerf, K. J., Lolkema, J. S., Otto, R., Neijssel, O. M., Stouthamer, A. H., Harder, W., ... & Westerhoff, H. V. (1982). Energetics of microbial growth: an analysis of the relationship between growth and its mechanistic basis by mosaic non-equilibrium thermodynamics. FEMS Microbiology Letters, 15(1), 7-17. [CrossRef]
  55. Holmes, E. C., Goldstein, S. A., Rasmussen, A. L., Robertson, D. L., Crits-Christoph, A., Wertheim, J. O., Anthony, S. J., Barclay, W. S., Boni, M. F., Doherty, P. C., Farrar, J., Geoghegan, J. L., Jiang, X., Leibowitz, J. L., Neil, S. J. D., Skern, T., Weiss, S. R., Worobey, M., Andersen, K. G., Garry, R. F., … Rambaut, A. (2021). The origins of SARS-CoV-2: A critical review. Cell, 184(19), 4848–4856. [CrossRef]
  56. Hu, B., Guo, H., Zhou, P., & Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature reviews. Microbiology, 19(3), 141–154. [CrossRef]
  57. Huang, Y., Yang, C., Xu, Xf. et al. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 41, 1141–1149. [CrossRef]
  58. Hurst Jr, J. E., & Harrison, B.K. (1992). Estimation of liquid and solid heat capacities using a modified Kopp's rule. Chemical Engineering Communications, 112(1), 21-30. [CrossRef]
  59. Ichikawa, T., Torii, S., Suzuki, H., Takada, A., Suzuki, S., Nakajima, M., Tampo, A., & Kakinoki, Y. (2022). Mutations in the nonstructural proteins of SARS-CoV-2 may contribute to adverse clinical outcome in patients with COVID-19. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 122, 123–129. [CrossRef]
  60. Jack, A., Ferro, L. S., Trnka, M. J., Wehri, E., Nadgir, A., Nguyenla, X., Costa, K., Stanley, S., Schaletzky, J., & Yildiz, A. (2021). SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA. bioRxiv : the preprint server for biology, 2020.09.14.295824. [CrossRef]
  61. Jackson, C.B., Farzan, M., Chen, B. et al. (2022). Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23, 3–20. [CrossRef]
  62. Kaniadakis, G., Baldi, M.M., Deisboeck, T.S. et al. (2020). The κ-statistics approach to epidemiology. Sci Rep 10, 19949. [CrossRef]
  63. Ke, Z., Oton, J., Qu, K. et al. (2020). Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498–502. [CrossRef]
  64. Khan, J., Asoom, L. I. A., Khan, M., Chakrabartty, I., Dandoti, S., Rudrapal, M., & Zothantluanga, J. H. (2021). Evolution of RNA viruses from SARS to SARS-CoV-2 and diagnostic techniques for COVID-19: a review. Beni-Suef University journal of basic and applied sciences, 10(1), 60. [CrossRef]
  65. Khare, S., et al (2021) GISAID’s Role in Pandemic Response. China CDC Weekly, 3(49): 1049-1051. 1051. [CrossRef]
  66. Kordyukova, L. V., Moiseenko, A. V., Serebryakova, M. V., Shuklina, M. A., Sergeeva, M. V., Lioznov, D. A., & Shanko, A. V. (2023). Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine. Viruses, 15(2), 480. [CrossRef]
  67. Kumar, R., Srivastava, Y., Muthuramalingam, P., Singh, S. K., Verma, G., Tiwari, S., Tandel, N., Beura, S. K., Panigrahi, A. R., Maji, S., Sharma, P., Rai, P. K., Prajapati, D. K., Shin, H., & Tyagi, R. K. (2023). Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. Viruses, 15(4), 856. [CrossRef]
  68. Kumar, S., & Saxena, S. K. (2021). Structural and molecular perspectives of SARS-CoV-2. Methods (San Diego, Calif.), 195, 23–28. [CrossRef]
  69. Lee, J. Y., Wing, P. A. C., Gala, D. S., Noerenberg, M., Järvelin, A. I., Titlow, J., Zhuang, X., Palmalux, N., Iselin, L., Thompson, M. K., Parton, R. M., Prange-Barczynska, M., Wainman, A., Salguero, F. J., Bishop, T., Agranoff, D., James, W., Castello, A., McKeating, J. A., & Davis, I. (2022). Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences. eLife, 11, e74153. [CrossRef]
  70. Lucia, U., Grisolia, G., & Deisboeck, T. S. (2021). Thermodynamics and SARS-CoV-2: neurological effects in post-Covid 19 syndrome. Atti della Accademia Peloritana dei Pericolanti, 99(2), A3. [CrossRef]
  71. Lucia, U., Grisolia, G., & Deisboeck, T. S. (2020a). Seebeck-like effect in SARS-CoV-2 bio-thermodynamics. Atti della Accademia Peloritana dei Pericolanti-Classe di Scienze Fisiche, Matematiche e Naturali, 98(2), 6. [CrossRef]
  72. Lucia, U., Deisboeck, T. S., & Grisolia, G. (2020b). Entropy-based pandemics forecasting. Frontiers in Physics, 8, 274. [CrossRef]
  73. Magazine, N., Zhang, T., Wu, Y., McGee, M. C., Veggiani, G., & Huang, W. (2022). Mutations and Evolution of the SARS-CoV-2 Spike Protein. Viruses, 14(3), 640. [CrossRef]
  74. Mandala, V.S., McKay, M.J., Shcherbakov, A.A. et al. (2020). Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol 27, 1202–1208. [CrossRef]
  75. Maskow, T., Kiesel, B., Schubert, T., Yong, Z., Harms, H., & Yao, J. (2010). Calorimetric real time monitoring of lambda prophage induction. Journal of virological methods, 168(1-2), 126–132. [CrossRef]
  76. Mesquita, F. S., Abrami, L., Sergeeva, O., Turelli, P., Qing, E., Kunz, B., Raclot, C., Paz Montoya, J., Abriata, L. A., Gallagher, T., Dal Peraro, M., Trono, D., D'Angelo, G., & van der Goot, F. G. (2021). S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity. Developmental cell, 56(20), 2790–2807.e8. 2807. [CrossRef]
  77. Motsa, B. B., & Stahelin, R. V. (2021). Lipid-protein interactions in virus assembly and budding from the host cell plasma membrane. Biochemical Society transactions, 49(4), 1633–1641. [CrossRef]
  78. Nasir, A., Aamir, U. B., Kanji, A., Bukhari, A. R., Ansar, Z., Ghanchi, N. K., Masood, K. I., Samreen, A., Islam, N., Ghani, S., Syed, M. A., Wassan, M., Mahmood, S. F., & Hasan, Z. (2023). Tracking SARS-CoV-2 variants through pandemic waves using RT-PCR testing in low-resource settings. PLOS global public health, 3(6), e0001896. [CrossRef]
  79. NCBI (2023a). SARS-CoV-2 Variants Overview [Online] National Center for Biotechnology Information. Available online: https://www.ncbi.nlm.nih.gov/activ (accessed on 5 September 2023).
  80. NCBI (2023b). NCBI Database [Online]. National Center for Biotechnology Information. Available online: https://www.ncbi.nlm.nih.gov/ (accessed on 24 September 2023).
  81. NCBI (2023c). Nucleocapsid phosphoprotein [Severe acute respiratory syndrome coronavirus 2] [Online]. National Center for Biotechnology Information. Available online: https://www.ncbi.nlm.nih.gov/protein/QIK50455.1 (accessed on 24 September 2023).
  82. NCBI (2023d). Membrane protein [Severe acute respiratory syndrome coronavirus 2] [Online] National Center for Biotechnology Information. Available online: https://www.ncbi.nlm.nih.gov/protein/QHR63293.1 (accessed on 24 September 2023).
  83. NCBI (2023e). Spike glycoprotein [Severe acute respiratory syndrome coronavirus 2] [Online] National Center for Biotechnology Informatio. Available online: https://www.ncbi.nlm.nih.gov/protein/QHR63290.2 (accessed on 24 September 2023).
  84. Neuman, B.W. and Buchmeier, M.J. (2016). Supramolecular architecture of the coronavirus particle. Advances in Virus Research, 96, 1-27. [CrossRef]
  85. Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., Droese, B., Klaus, J. P., Makino, S., Sawicki, S. G., Siddell, S. G., Stamou, D. G., Wilson, I. A., Kuhn, P., & Buchmeier, M. J. (2011). A structural analysis of M protein in coronavirus assembly and morphology. Journal of structural biology, 174(1), 11–22. [CrossRef]
  86. Neuman, B. W., Adair, B. D., Yoshioka, C., Quispe, J. D., Orca, G., Kuhn, P., Milligan, R. A., Yeager, M., & Buchmeier, M. J. (2006). Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. Journal of virology, 80(16), 7918–7928. [CrossRef]
  87. Özilgen, M., & Yilmaz, B. (2021). COVID-19 disease causes an energy supply deficit in a patient. International journal of energy research, 45(2), 1157–1160. [CrossRef]
  88. Ozilgen, M. and Sorgüven, E. (2017). Biothermodynamics: Principles and Applications. Boca Raton: CRC Press. [CrossRef]
  89. Patel, S.A. and Erickson, L.E. (1981). Estimation of heats of combustion of biomass from elemental analysis using available electron concepts. Biotechnology and Bioengineering, 23, 2051-2067. [CrossRef]
  90. Pateras, J., Vaidya, A., & Ghosh, P. (2022). Network Thermodynamics-Based Scalable Compartmental Model for Multi-Strain Epidemics. Mathematics, 10(19), 3513. [CrossRef]
  91. Perdikari, T. M., Murthy, A. C., Ryan, V. H., Watters, S., Naik, M. T., & Fawzi, N. L. (2020). SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs. The EMBO journal, 39(24), e106478. [CrossRef]
  92. Popovic, M.E., Mihailović, M. and Pavlović, S. (2023a). Upcoming epidemic storm: Empirical formulas, biosynthesis reactions, thermodynamic properties and driving forces of multiplication of the omicron XBB.1.9.1, XBF and XBB.1.16 (Arcturus) variants of SARS-CoV-2. Microbial Risk Analysis, 25, 100273. [CrossRef]
  93. Popovic, M., Pantović Pavlović, M., & Pavlović, M. (2023b). Ghosts of the past: Elemental composition, biosynthesis reactions and thermodynamic properties of Zeta P.2, Eta B.1.525, Theta P.3, Kappa B.1.617.1, Iota B.1.526, Lambda C.37 and Mu B.1.621 variants of SARS-CoV-2. Microbial risk analysis, 24, 100263. [CrossRef]
  94. Popovic, M., Tadić, V., & Mihailović, M. (2023c). From genotype to phenotype with biothermodynamics: empirical formulas, biosynthesis reactions and thermodynamic properties of preproinsulin, proinsulin and insulin molecules. Journal of biomolecular structure & dynamics, 1–13. [CrossRef]
  95. Popovic, M. (2023a). SARS-CoV-2 strain wars continues: Chemical and thermodynamic characterization of live matter and biosynthesis of Omicron BN.1, CH.1.1 and XBC variants. Microbial Risk Analysis, 24, 100260. [CrossRef]
  96. Popovic M. E. (2023b). XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2. Microbiological research, 270, 127337. [CrossRef]
  97. Popovic M. (2023c). Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants. Microbial risk analysis, 23, 10025. [CrossRef]
  98. Popovic M. (2023d). The SARS-CoV-2 Hydra, a tiny monster from the 21st century: Thermodynamics of the BA.5.2 and BF.7 variants. Microbial risk analysis, 23, 100249. [CrossRef]
  99. Popovic, M. (2023e). Thermodynamics of Bacteria-Phage Interactions: T4 and Lambda Bacteriophages, and E. Coli Can Coexist in Natural Ecosystems due to the Ratio of their Gibbs Energies of Biosynthesis. Thermal Science, 27(1), 411-431. [CrossRef]
  100. Popovic, M., & Popovic, M. (2022). Strain Wars: Competitive interactions between SARS-CoV-2 strains are explained by Gibbs energy of antigen-receptor binding. Microbial risk analysis, 21, 100202. [CrossRef]
  101. Popovic, M. (2022a). Formulas for death and life: Chemical composition and biothermodynamic properties of Monkeypox (MPV, MPXV, HMPXV) and Vaccinia (VACV) viruses. Thermal Science, 26(6A), 4855-4868. [CrossRef]
  102. Popovic M. (2022b). Beyond COVID-19: Do biothermodynamic properties allow predicting the future evolution of SARS-CoV-2 variants?. Microbial risk analysis, 22, 100232. [CrossRef]
  103. Popovic, M. (2022c). Biothermodynamics of Viruses from Absolute Zero (1950) to Virothermodynamics (2022). Vaccines, 10(12), 2112. [CrossRef]
  104. Popovic, M. (2022d). Omicron BA.2.75 Sublineage (Centaurus) Follows the Expectations of the Evolution Theory: Less Negative Gibbs Energy of Biosynthesis Indicates Decreased Pathogenicity. Microbiology Research, 13(4), 937–952. [CrossRef]
  105. Popovic, M. (2022e). Strain wars 3: Differences in infectivity and pathogenicity between Delta and Omicron strains of SARS-CoV-2 can be explained by thermodynamic and kinetic parameters of binding and growth. Microbial Risk Analysis, 22, 100217. 0021. [CrossRef]
  106. Popovic, M. (2022f). Strain Wars 4 - Darwinian evolution through Gibbs’ glasses: Gibbs energies of binding and growth explain evolution of SARS-CoV-2 from Hu-1 to BA.2. Virology, 575, 36-42. [CrossRef]
  107. Popovic M. (2022g). Atom counting method for determining elemental composition of viruses and its applications in biothermodynamics and environmental science. Computational biology and chemistry, 96, 107621. [CrossRef]
  108. Popovic, M. (2022h). Why doesn’t Ebola virus cause pandemics like SARS-CoV-2? Microbial Risk Analysis, 22, 100236. [CrossRef]
  109. Popovic, M., Stenning, G. B. G., Göttlein, A., & Minceva, M. (2021). Elemental composition, heat capacity from 2 to 300 K and derived thermodynamic functions of 5 microorganism species. Journal of biotechnology, 331, 99–107. [CrossRef]
  110. Popovic, M., & Minceva, M. (2021). Coinfection and Interference Phenomena Are the Results of Multiple Thermodynamic Competitive Interactions. Microorganisms, 9(10), 2060. [CrossRef]
  111. Popovic, M. and Minceva, M. (2020a). A thermodynamic insight into viral infections: do viruses in a lytic cycle hijack cell metabolism due to their low Gibbs energy? Heliyon, 6(5), e03933. [CrossRef]
  112. Popovic, M., & Minceva, M. (2020b). Thermodynamic insight into viral infections 2: empirical formulas, molecular compositions and thermodynamic properties of SARS, MERS and SARS-CoV-2 (COVID-19) viruses. Heliyon, 6(9), e04943.
  113. Popovic, M. E., & Minceva, M. (2020c). Thermodynamic properties of human tissues. Thermal Science, 24(6 Part B), 4115-4133. [CrossRef]
  114. Popovic M. (2019). Thermodynamic properties of microorganisms: determination and analysis of enthalpy, entropy, and Gibbs free energy of biomass, cells and colonies of 32 microorganism species. Heliyon, 5(6), e01950. [CrossRef]
  115. Rahbar, M.R., Jahangiri, A., Khalili, S. et al. (2021). Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis. Sci Rep 11, 23622. [CrossRef]
  116. Rahman, S., Hossain, M. J., Nahar, Z., Shahriar, M., Bhuiyan, M. A., & Islam, M. R. (2022). Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic. Environmental health insights, 16, 11786302221129396. [CrossRef]
  117. Rajagopalan, M. (2021). Knowing Our Rival–Coronaviridae: The Virus Family. IntechOpen. [CrossRef]
  118. Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021). Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines, 9(10), 1195. [CrossRef]
  119. Riedel, S., Hobden, J.A., Miller, S., Morse, S.A., Mietzner, T.A., Detrick, B., Mitchell, T.G., Sakanari, J.A., Hotez, P. and Mejia, R. (2019). Jawetz, Melnick and Adelberg’s Medical Microbiology, 28th ed., New York: McGraw-Hill. ISBN-13: 978-1260012026.
  120. Sanjuán, R., Domingo-Calap, P. (2016). Mechanisms of viral mutation. Cell. Mol. Life Sci. 73, 4433–4448. [CrossRef]
  121. Satarker, S., & Nampoothiri, M. (2020). Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Archives of medical research, 51(6), 482–491. [CrossRef]
  122. Sayers, E. W., Bolton, E. E., Brister, J. R., Canese, K., Chan, J., Comeau, D. C., Connor, R., Funk, K., Kelly, C., Kim, S., Madej, T., Marchler-Bauer, A., Lanczycki, C., Lathrop, S., Lu, Z., Thibaud-Nissen, F., Murphy, T., Phan, L., Skripchenko, Y., Tse, T., … Sherry, S. T. (2022). Database resources of the national center for biotechnology information. Nucleic acids research, 50(D1), D20–D26. [CrossRef]
  123. Schoeman, D., Fielding, B.C. (2019). Coronavirus envelope protein: current knowledge. Virol J 16, 69. [CrossRef]
  124. Schulte, M. B., Draghi, J. A., Plotkin, J. B., & Andino, R. (2015). Experimentally guided models reveal replication principles that shape the mutation distribution of RNA viruses. eLife, 4, e03753. [CrossRef]
  125. Senthilazhagan, K., Sakthimani, S., Kallanja, D., & Venkataraman, S. (2023). SARS-CoV-2: analysis of the effects of mutations in non-structural proteins. Archives of virology, 168(7), 186. Archives of virology. [CrossRef]
  126. Shu, Y. and McCauley, J. (2017) GISAID: from vision to reality. EuroSurveillance, 22(13). [CrossRef]
  127. Şimşek, B., Özilgen, M., & Utku, F. Ş. (2021). How much energy is stored in SARS-CoV-2 and its structural elements?. Energy Storage, e298. [CrossRef]
  128. Singh, H., Dahiya, N., Yadav, M., & Sehrawat, N. (2022). Emergence of SARS-CoV-2 New Variants and Their Clinical Significance. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2022, 733630. [CrossRef]
  129. Souza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., Magalhaes, I. C. L., Castelo-Branco, D. S. C. M., Montenegro, R. C., & de Andrade, C. R. (2022). The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. International journal of biological macromolecules, 208, 105–125. [CrossRef]
  130. Taha, B. A., Al-Jubouri, Q., Al Mashhadany, Y., Hafiz Mokhtar, M. H., Bin Zan, M. S. D., Bakar, A. A. A., & Arsad, N. (2023). Density estimation of SARS-CoV2 spike proteins using super pixels segmentation technique. Applied soft computing, 138, 110210. [CrossRef]
  131. hakur, V., Bhola, S., Thakur, P. et al. (2022). Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection 50, 309–325. [CrossRef]
  132. Thornton, W. M. (1917). XV. The relation of oxygen to the heat of combustion of organic compounds. The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science, 33(194), 196-203. [CrossRef]
  133. Trancossi, M., Carli, C., Cannistraro, G., Pascoa, J., & Sharma, S. (2021). Could thermodynamics and heat and mass transfer research produce a fundamental step advance toward and significant reduction of SARS-COV-2 spread?. International journal of heat and mass transfer, 170, 120983. [CrossRef]
  134. Troyano-Hernáez, P., Reinosa, R., & Holguín, Á. (2021). Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week. Viruses, 13(2), 243. 20 September. [CrossRef]
  135. V’kovski, P., Kratzel, A., Steiner, S. et al. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19, 155–170. [CrossRef]
  136. Villa, T. G., Abril, A. G., Sánchez, S., de Miguel, T., & Sánchez-Pérez, A. (2021). Animal and human RNA viruses: genetic variability and ability to overcome vaccines. Archives of microbiology, 203(2), 443–464. [CrossRef]
  137. Von Stockar, U. (2013a). Live cells as open non-equilibrium systems. In Urs von Stockar, ed., Biothermodynamics: The Role of Thermodynamics in Biochemical Engineering, Lausanne: EPFL Press, 475-534.
  138. Von Stockar, U. (2013b). Biothermodynamics of live cells: energy dissipation and heat generation in cellular structures. In: Biothermodynamics: the role of thermodynamics in Biochemical Engineering, von Stockar, U., ed., Lausanne: EPFL Press, pp. 475-534.
  139. von Stockar, U., & Liu, J. (1999). Does microbial life always feed on negative entropy? Thermodynamic analysis of microbial growth. Biochimica et biophysica acta, 1412(3), 191–211. [CrossRef]
  140. Wang, W., Chen, J., Yu, X., & Lan, H. Y. (2022). Signaling mechanisms of SARS-CoV-2 Nucleocapsid protein in viral infection, cell death and inflammation. International journal of biological sciences, 18(12), 4704–4713. [CrossRef]
  141. Westerhoff, H. V., Lolkema, J. S., Otto, R., & Hellingwerf, K. J. (1982). Thermodynamics of growth. Non-equilibrium thermodynamics of bacterial growth. The phenomenological and the mosaic approach. Biochimica et biophysica acta, 683(3-4), 181–220. [CrossRef]
  142. WHO (2023a). WHO Coronavirus (COVID-19) Dashboard [Online] World Health Organization. Available online: https://covid19.who.int/ (accessed on 31 August 2023).
  143. WHO (2023b). Tracking SARS-CoV-2 variants [Online] World Health Organization. Available online: https://www.who.int/activities/tracking-SARS-CoV-2-variants (accessed on 5 September 2023).
  144. WHO (2021). WHO-convened Global Study of Origins of SARS-CoV-2: China Part. [Online] World Health Organization. Available online: https://www.who.int/docs/default-source/coronaviruse/who-convened-global-study-of-origins-of-sars-cov-2-china-part-joint-report.pdf (accessed on 2 September 2023).
  145. Wu, W., Cheng, Y., Zhou, H., Sun, C., & Zhang, S. (2023). The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virology journal, 20(1), 6. [CrossRef]
  146. Wu, C., Qavi, A. J., Hachim, A., Kavian, N., Cole, A. R., Moyle, A. B., Wagner, N. D., Sweeney-Gibbons, J., Rohrs, H. W., Gross, M. L., Peiris, J. S. M., Basler, C. F., Farnsworth, C. W., Valkenburg, S. A., Amarasinghe, G. K., & Leung, D. W. (2021). Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain. iScience, 24(6), 102681. [CrossRef]
  147. Yang, Y., Xiao, Z., Ye, K. et al. (2020). SARS-CoV-2: characteristics and current advances in research. Virol J 17, 117. [CrossRef]
  148. Yao, H., Song, Y., Chen, Y., Wu, N., Xu, J., Sun, C., Zhang, J., Weng, T., Zhang, Z., Wu, Z., Cheng, L., Shi, D., Lu, X., Lei, J., Crispin, M., Shi, Y., Li, L., & Li, S. (2020). Molecular Architecture of the SARS-CoV-2 Virus. Cell, 183(3), 730–738.e13. [CrossRef]
  149. Yilmaz, B., Ercan, S., Akduman, S., & Özilgen, M. (2020). Energetic and exergetic costs of COVID-19 infection on the body of a patient. International Journal of Exergy, 32(3), 314-327. [CrossRef]
  150. Zeng, C., Evans, J. P., King, T., Zheng, Y. M., Oltz, E. M., Whelan, S. P. J., Saif, L., Peeples, M. E., & Liu, S. L. (2021). SARS-CoV-2 Spreads through Cell-to-Cell Transmission. bioRxiv : the preprint server for biology, 2021.06.01.446579. [CrossRef]
  151. Zhang, L., Richards, A., Barrasa, M. I., Hughes, S. H., Young, R. A., & Jaenisch, R. (2021). Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proceedings of the National Academy of Sciences of the United States of America, 118(21), e2105968118. [CrossRef]
  152. Zhu, Z., Lian, X., Su, X. et al. (2020). From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res 21, 224. [CrossRef]
Table 1. Empirical formulas and molar masses of the Omicron BA.2.86 Pirola variant of SARS-CoV-2. Empirical formulas have the general form CnCHnHOnONnNPnPSnS, where nC, nH, nO, nN, nP and nS are numbers of C, H, O, N, P and S atoms in the empirical formula, respectively. Molar masses were reported in two forms: molar mass of the empirical formula, Mr, and total molar mass of the macromolecular assembly (entire virus particle or entire nucleocapsid), Mr(tot).
Table 1. Empirical formulas and molar masses of the Omicron BA.2.86 Pirola variant of SARS-CoV-2. Empirical formulas have the general form CnCHnHOnONnNPnPSnS, where nC, nH, nO, nN, nP and nS are numbers of C, H, O, N, P and S atoms in the empirical formula, respectively. Molar masses were reported in two forms: molar mass of the empirical formula, Mr, and total molar mass of the macromolecular assembly (entire virus particle or entire nucleocapsid), Mr(tot).
Name nC nH nO nN nP nS Mr (g/C-mol) Mr(tot) (MDa)
BA.2.86 virus particle 1 1.639023 0.284130 0.230031 0.006440 0.003765 21.75 219.7
BA.2.86 nucleocapsid 1 1.570946 0.343118 0.312432 0.006007 0.003349 23.75 117.6
Table 2. Thermodynamic properties of live matter of the Omicron BA.2.86 variant of SARS-CoV-2: standard enthalpy of formation, ΔfH⁰, standard molar entropy, Sm⁰, and standard Gibbs energy of formation, ΔfG⁰.
Table 2. Thermodynamic properties of live matter of the Omicron BA.2.86 variant of SARS-CoV-2: standard enthalpy of formation, ΔfH⁰, standard molar entropy, Sm⁰, and standard Gibbs energy of formation, ΔfG⁰.
Name ΔfH⁰ (kJ/C-mol) Sm⁰ (J/C-mol K) ΔfG⁰ (kJ/C-mol)
BA.2.86 virus particle -64.43 30.70 -24.64
BA.2.86 nucleocapsid -75.41 32.47 -33.32
Table 3. Biosynthesis stoichiometry for the Omicron BA.2.86 variant of SARS-CoV-2. The general biosynthesis reaction has the form (Amino acid) + CH2O + O2 + HPO42- + HCO3- → (Bio) + SO22- + H2O + H2CO3. “Amino acid” represents a mixture of amino acids with the formula CH1.798O0.4831N0.2247S0.022472. “Bio” represents the empirical formula of live matter from Table 1.
Table 3. Biosynthesis stoichiometry for the Omicron BA.2.86 variant of SARS-CoV-2. The general biosynthesis reaction has the form (Amino acid) + CH2O + O2 + HPO42- + HCO3- → (Bio) + SO22- + H2O + H2CO3. “Amino acid” represents a mixture of amino acids with the formula CH1.798O0.4831N0.2247S0.022472. “Bio” represents the empirical formula of live matter from Table 1.
Name Reactants → Products
Amino acid CH2O O2 HPO42- HCO3- Bio SO42- H2O H2CO3
BA.2.86 virus particle 1.023637 0.010469 0.000000 0.006440 0.025596 → 1 0.019238 0.067397 0.059701
BA.2.86 nucleocapsid 1.390323 0.000000 0.492478 0.006007 0.043774 → 1 0.027894 0.055049 0.434097
Table 4. Thermodynamic properties of biosynthesis for the Omicron BA.2.86 variant of SARS-CoV-2: standard enthalpy of biosynthesis, ΔbsH⁰, standard entropy of biosynthesis, ΔbsS⁰, and standard Gibbs energy of biosynthesis, ΔbsG⁰.
Table 4. Thermodynamic properties of biosynthesis for the Omicron BA.2.86 variant of SARS-CoV-2: standard enthalpy of biosynthesis, ΔbsH⁰, standard entropy of biosynthesis, ΔbsS⁰, and standard Gibbs energy of biosynthesis, ΔbsG⁰.
Name ΔbsH⁰ (kJ/C-mol) ΔbsS⁰ (J/C-mol K) ΔbsG⁰ (kJ/C-mol)
BA.2.86 virus particle -4.80 6.94 -6.94
BA.2.86 nucleocapsid -232.88 -37.48 -221.75
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated